Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to participate in the Credit Suisse Virtual Healthcare Conference on Nov. 10.

Zoetis to Participate in the Credit Suisse 2020 Virtual Healthcare Conference

Is (ZTS) Outperforming Other Medical Stocks This Year?

Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?

Jazz Pharmaceuticals

SPDR S&P Pharmaceuticals ETF

Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.

Pharma Stocks Poised to Move Higher

Chewy

Covetrus Inc

Freshpet

IDEXX Laboratories

PetMed Express

J. M. Smucker

Chewy, Zoetis and FreshPet are just a couple of the names on our list of pet stocks to buy. Let's look at this growing industry more closely.

7 Pet Stocks to Adopt Today 

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--Zoetis declares fourth quarter 2020 dividend.

Zoetis Declares Fourth Quarter 2020 Dividend

These four pet stocks should benefit from both increased ownership and higher spending as the "humanization" of pets continues. The post 4 Pet Stocks Catering to Stay-at-Home Trends appeared first on InvestorPlace.

4 Pet Stocks Catering to Stay-at-Home Trends

British American Tobacco

Charter Communications

Diageo

Alphabet

Imperial Brands PLC

L'Oreal SA

Marriott

Altria

PayPal

We highlight the most attractive opportunities this month, by reviewing notable price moves and rating changes in our research.

Librarian Capital's Monthly Top Buys And Price Moves - September 2020

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to report third quarter 2020 financial results on Nov. 5.

Zoetis to Host Webcast and Conference Call on Third Quarter 2020 Financial Results

One of my friends and I were discussing the markets, and he drew my attention to a company that I was not familiar with: Covetrus (NASDAQ:CVET).
The post The Pet Health Care Market Continues to Pay Out appeared first on InvestorPlace.

The Pet Health Care Market Continues to Pay Out

Zoetis (NYSE:ZTS), a class-leading animal health and vaccine company, including animal-to-human virus vaccines, used to be a subsidiary of pharmaceutical giant Pfizer (NYSE:PFE), but it spun off in 2013.
The post Zoetis is Higher Than Ever Thanks to Pet (and Farm) Spending appeared first on InvestorPlace.

Zoetis is Higher Than Ever Thanks to Pet (and Farm) Spending

Gilead Sciences

Regeneron Pharmaceuticals

Takeda Pharmaceutical

vTv Therapeutics

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

5 of the Best Pharmaceutical Stocks to Buy Right Now

Amazon

Merck

Nestle SA

Despite the economic challenges of the pandemic, Americans are spoiling their pets. Profit from that hot market with these top growth stocks.

5 Hot Growth Stocks to Buy With Fido in Mind

Considering the higher cost debt can be refinanced at a much lower interest rate, I expect Zoetis to return to a share buyback program rather than paying down debt.

Zoetis: Strong, Resilient, But Too Expensive For Me

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis will present at the 18th Annual Morgan Stanley Healthcare Conference on Wednesday, Sept.

Zoetis to Participate in the 18th Annual Morgan Stanley Healthcare Conference

AstraZeneca

Horizon Pharma

Eli Lilly

Dr. Reddy's Labs

Repligen

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

6 of the Best Pharmaceutical Stocks to Buy Today

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Why Is Zoetis (ZTS) Down 2.5% Since Last Earnings Report?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

Food supply chains were disturbed by the pandemic, but Zoetis is confident looking into the future.

How This Animal Health Company Was Disrupted by the Coronavirus

BlackBerry

LM Ericsson Telefon

Hannon Armstrong Sustainable Infrastructure Capital

Hercules Capital

Some of the best tech stocks to buy are lesser known companies leading key innovations. Here are six oddballs many investors are overlooking.

6 Forgotten Tech Stocks to Buy Now

These are three of best pet stocks to buy now. Each is riding the recent wave of pet ownership due to the novel coronavirus.

3 of the Best Pet Stocks to Buy Now

Blackrock Inc

Salesforce

Deere & Company

Microsoft

Progressive

Environmental, Social and Governance investing may seem counter to maximizing profits, but the best ESG stocks deliver for all stakeholders.

7 ESG Stocks That Will Deliver for Every Stakeholder

ORLANDO, Fla., Aug. 17, 2020 /PRNewswire/ -- The North American Veterinary Community (NAVC) today announced the opening of the Zoetis VMX Virtual Expo Hall booth, providing year-round opportunities for veterinary professionals to engage with and learn about the company's new products,.

NAVC Announces Zoetis Joins VMX Virtual Expo Hall Opening The Doors For New Interactive And Innovative Ways To Engage And Educate Veterinary Professionals Year-Round

Zoetis' (ZTS) CEO Kristin Peck on Q2 2020 Results - Earnings Call Transcript

Its companion-animal products continue to be the sweet spot for the animal health company.

News for Zoetis Stock (ZTS)